04:37:52 Europe / Stockholm
Svenska | English

Alzinova

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-14 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-30 Ordinarie utdelning ALZ 0.00 SEK
2024-05-29 Årsstämma 2024
2024-05-28 Kvartalsrapport 2024-Q1
2024-02-28 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-08-17 Kvartalsrapport 2023-Q2
2023-05-30 Årsstämma 2023
2023-05-25 Ordinarie utdelning ALZ 0.00 SEK
2023-05-17 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-11-01 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Kvartalsrapport 2022-Q1
2022-05-19 Ordinarie utdelning ALZ 0.00 SEK
2022-05-18 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-19 Kvartalsrapport 2021-Q1
2021-05-19 Ordinarie utdelning ALZ 0.00 SEK
2021-05-18 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-05-17 Ordinarie utdelning ALZ 0.00 SEK
2020-05-15 Kvartalsrapport 2020-Q1
2020-05-14 Årsstämma 2020
2020-02-27 Extra Bolagsstämma 2020
2020-02-26 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-17 Kvartalsrapport 2019-Q1
2019-05-17 Ordinarie utdelning ALZ 0.00 SEK
2019-05-16 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-08-29 Kvartalsrapport 2018-Q2
2018-05-18 Ordinarie utdelning ALZ 0.00 SEK
2018-05-18 Kvartalsrapport 2018-Q1
2018-05-17 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-03 Kvartalsrapport 2017-Q3
2017-08-29 Kvartalsrapport 2017-Q2
2017-05-19 Kvartalsrapport 2017-Q1
2017-05-18 Ordinarie utdelning ALZ 0.00 SEK
2017-05-17 Årsstämma 2017
2017-02-24 Bokslutskommuniké 2016
2016-11-28 Kvartalsrapport 2016-Q3
2016-08-29 Kvartalsrapport 2016-Q2
2016-05-19 Ordinarie utdelning ALZ 0.00 SEK
2016-05-18 Kvartalsrapport 2016-Q1
2016-05-18 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Alzinova är ett bioteknikbolag. Bolaget är specialiserat inom terapeutiskt behandling av Alzheimers och bedriver idag forskning och utveckling av peptider som vidareutvecklas som vaccin. Utöver utvecklar bolaget även diverse forskningsverktyg inom arbetsområdet. Störst verksamhet återfinns inom den nordiska marknaden. Bolaget grundades under 2011 och har sitt huvudkontor i Göteborg.
Alzinova presents at investor meetings in March
2024-03-05 13:20:00

Alzinova AB (publ) will present the company to investors at two capital market events in March 2024. First out is Penser By Carnegie's company day on 7 March, followed by Redeye Theme: Alzheimer on 21 March.

Penser by Carnegie company day, March 7
At Penser by Carnegie's company day on 7 March, Alzinova's CEO Kristina Torfgård will present the company and the latest developments. The presentation, which will be broadcast live, will be held at 9.05-9.30 and can be viewed at the following link: https://www.youtube.com/playlist?list=PLFeVXfrcmwBBZOh_NjsLu2mH3-KYatyIY

Redeye Theme: Alzheimer’s disease, March 21
Drug development in the field of Alzheimer's disease is an ongoing hot topic and society is now facing an important paradigm shift with the commercialisation of the first disease-modifying therapies. Redeye has invited Alzinova and two other companies - three prominent Swedish Alzheimer's companies - to a panel discussion to talk about the science behind their drug candidates, the remaining need and what it will take to successfully launch a new generation of Alzheimer's drugs. CEO Kristina Torfgård will participate in the panel. Access the event here: https://www.redeye.se/events/975970/redeye-theme-alzheimer-2?tab=attendingcompanies

For more information, please contact:
Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail:  kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Attachments
Alzinova presents at investor meetings in March

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden